NASDAQ:DRRX - DURECT Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.17 -0.03 (-1.36 %)
(As of 06/18/2018 04:00 PM ET)
Previous Close$2.20
Today's Range$2.15 - $2.24
52-Week Range$0.75 - $2.55
Volume826,600 shs
Average Volume837,451 shs
Market Capitalization$355.76 million
P/E Ratio-72.33
Dividend YieldN/A


DURECT logoDURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials in their products for pharmaceutical and medical devices under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's advanced oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including REMOXY ER, an investigational extended release pain relief drug based on ORADUR technology; and POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has collaboration agreements with Sandoz AG; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Zogenix, Inc.; and Pain Therapeutics, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.

Receive DRRX News and Ratings via Email

Sign-up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio0.50
Current Ratio4.61
Quick Ratio4.32


Trailing P/E Ratio-72.33
Forward P/E Ratio-9.43
P/E GrowthN/A

Sales & Book Value

Annual Sales$49.17 million
Price / Sales7.14
Cash FlowN/A
Price / CashN/A
Book Value$0.14 per share
Price / Book15.50


EPS (Most Recent Fiscal Year)($0.03)
Net Income$-3,690,000.00
Net Margins-8.06%
Return on Equity-25.82%
Return on Assets-7.04%


Outstanding Shares161,710,000

DURECT (NASDAQ:DRRX) Frequently Asked Questions

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) released its quarterly earnings data on Wednesday, May, 2nd. The specialty pharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $0.01. The specialty pharmaceutical company earned $3.49 million during the quarter, compared to analysts' expectations of $4.20 million. DURECT had a negative return on equity of 25.82% and a negative net margin of 8.06%. View DURECT's Earnings History.

When is DURECT's next earnings date?

DURECT is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for DURECT.

What price target have analysts set for DRRX?

3 brokerages have issued 12-month price targets for DURECT's shares. Their forecasts range from $2.00 to $3.50. On average, they expect DURECT's stock price to reach $2.8333 in the next twelve months. View Analyst Ratings for DURECT.

Who are some of DURECT's key competitors?

Who are DURECT's key executives?

DURECT's management team includes the folowing people:
  • Dr. Felix Theeuwes, Co-Founder, Chairman & Distinguished Scientist (Age 80)
  • Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 61)
  • Mr. Matthew J. Hogan, CFO & Sec. (Age 58)
  • Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 61)
  • Mr. Michael H. Arenberg J.D., M.B.A., Sr. VP of Corp. & Bus. Devel.

Has DURECT been receiving favorable news coverage?

News stories about DRRX stock have been trending somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. DURECT earned a media sentiment score of 0.18 on Accern's scale. They also assigned news coverage about the specialty pharmaceutical company an impact score of 45.04 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are DURECT's major shareholders?

DURECT's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.10%), Northern Trust Corp (1.00%), Asymmetry Capital Management L.P. (0.47%), Millennium Management LLC (0.42%), Algert Global LLC (0.31%) and Mackay Shields LLC (0.11%). View Institutional Ownership Trends for DURECT.

Which major investors are selling DURECT stock?

DRRX stock was sold by a variety of institutional investors in the last quarter, including Asymmetry Capital Management L.P. and A.R.T. Advisors LLC. View Insider Buying and Selling for DURECT.

Which major investors are buying DURECT stock?

DRRX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Algert Global LLC, Mackay Shields LLC, Engineers Gate Manager LP, MetLife Investment Advisors LLC, Cubist Systematic Strategies LLC and Northern Trust Corp. View Insider Buying and Selling for DURECT.

How do I buy shares of DURECT?

Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $2.17.

How big of a company is DURECT?

DURECT has a market capitalization of $355.76 million and generates $49.17 million in revenue each year. The specialty pharmaceutical company earns $-3,690,000.00 in net income (profit) each year or ($0.03) on an earnings per share basis. DURECT employs 93 workers across the globe.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417.

MarketBeat Community Rating for DURECT (DRRX)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  168 (Vote Outperform)
Underperform Votes:  103 (Vote Underperform)
Total Votes:  271
MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote "Outperform" if you believe DRRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.